Holen Sie sich die Stockscreener-App
125.61
5.60%
-7.45
Schlusskurs vom Vortag:
$133.06
Offen:
$133
24-Stunden-Volumen:
3.35M
Relative Volume:
1.56
Marktkapitalisierung:
$16.66B
Einnahmen:
$1.08B
Nettoeinkommen (Verlust:
$-433.19M
KGV:
-36.94
EPS:
-3.4004
Netto-Cashflow:
$-225.09M
1W Leistung:
-3.15%
1M Leistung:
+40.32%
6M Leistung:
+23.12%
1J Leistung:
+159.47%
1-Tages-Spanne:
$124.91
$133.34
1-Wochen-Bereich:
$124.81
$134.28
52-Wochen-Spanne:
$40.35
$134.28
Guardant Health Inc Stock (GH) Company Profile
Firmenname
Guardant Health Inc
Sektor
Branche
Telefon
855-698-8887
Adresse
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
125.61 | 17.64B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Bestätigt | Canaccord Genuity | Buy |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-09-25 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-28 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-11-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-28 | Fortgesetzt | BTIG Research | Buy |
| 2022-02-24 | Bestätigt | Canaccord Genuity | Buy |
| 2022-02-24 | Bestätigt | Citigroup | Buy |
| 2022-02-24 | Bestätigt | Cowen | Outperform |
| 2022-02-24 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-24 | Bestätigt | SVB Leerink | Outperform |
| 2022-02-24 | Bestätigt | Stifel | Buy |
| 2022-02-24 | Bestätigt | Wells Fargo | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-11 | Eingeleitet | Stifel | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-06-12 | Eingeleitet | BTIG Research | Buy |
| 2020-02-21 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-08-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-04-16 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-04-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Bestätigt | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-29 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Guardant Health Inc Aktie (GH) Neueste Nachrichten
Goldman Sachs Initiates Guardant Health(GH.US) With Buy Rating, Announces Target Price $165 - Moomoo
Insider Sale: Director at $GH Sells 9,294 Shares - Moomoo
Insider Sell: Steve Krognes Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health director Steve Krognes sells $1.23m in stock By Investing.com - Investing.com Nigeria
Guardant Health director Steve Krognes sells $1.23m in stock - Investing.com
Guardant Health (NASDAQ: GH) director sells 9,294 shares in open-market trade - Stock Titan
Guardant Health, Inc. (GH) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
GH Initiates Coverage On Goldman Sachs -- Rating Set to Buy - GuruFocus
GH (Nasdaq) Form 144: Brokered RSU sale schedule via Stifel Nicolaus - Stock Titan
Guardant Health (NASDAQ: GH) Form 144: 2,000 shares listed, 3,000 sold - Stock Titan
How The Guardant Health (GH) Investment Story Is Evolving As Expectations Stay Unchanged - Yahoo Finance
AI-Powered Imaging Systems and Deep Learning Software Revolutionize Cancer Diagnostics Market Globally - GlobeNewswire Inc.
Guardant Health initiated with a Buy at Goldman Sachs - TipRanks
Goldman Sachs initiates Guardant Health stock with buy rating By Investing.com - Investing.com Canada
Guardant Health Insider Makes a Major Move With High-Value Stock Sale - TipRanks
Guardant Health (GH) director exercises options, sells 10,000 shares and holds 11,183 - Stock Titan
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Precision Trading with Guardant Health Inc. (GH) Risk Zones - Stock Traders Daily
GH Assumed by Wolfe Research -- Rating Set to Outperform - GuruFocus
Guardant Health Coverage Assumed by Wolfe Research at Outperform - Moomoo
This Evercore ISI Group Analyst Turns Bullish; Here Are Top 2 Upgrades For Tuesday - Benzinga
Guardant Health (NASDAQ: GH) director settles 154 RSUs, holds 19,516 shares - Stock Titan
Wolfe Research initiates Guardant Health stock with outperform rating By Investing.com - Investing.com Canada
3 Reasons GH is Risky and 1 Stock to Buy Instead - Yahoo Finance
Guardant Health, Inc. (GH) Stock Analysis: Navigating the Rapid Growth in Precision Oncology - DirectorsTalk Interviews
Blood testing is now included in screening recommendations for colon and rectal cancer - WQOW
Guardant Health Reaches New 52-Week High of $133.70 - Markets Mojo
Guardant Health director sells $130,060 of common stock - Investing.com UK
What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook - Kavout
Guardant Health director sells $130,060 of common stock By Investing.com - Investing.com Australia
Guardant Health (GH) director sells 1,000 shares, retains 639 - Stock Titan
Guardant Health stock hits 52-week high at 133.97 USD By Investing.com - Investing.com Nigeria
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $130 to $135 - Moomoo
Guardant Health stock hits 52-week high at 133.97 USD - Investing.com
Testing & Diagnostics Services Stocks Q1 Earnings: Guardant Health (NASDAQ:GH) Firing on All Cylinders - Yahoo Finance
Guardant Health Insider Sold Shares Worth $1,250,836, According to a Recent SEC Filing - Moomoo
Guardant Health Stock Rockets 40% With 8-Day Winning Streak - Trefis
8-Day Rally Sends Guardant Health Stock Up 40% - Trefis
Insider Sell: John Saia Sells 10,000 Shares of Guardant Health I - GuruFocus
Guardant Health CLO John Saia sells $1.25 million in shares By Investing.com - Investing.com Australia
Guardant Health CLO John Saia sells $1.25 million in shares - Investing.com
Guardant Health (GH) legal chief sells 10,000 shares in open-market trades - Stock Titan
Guardant Health (NASDAQ: GH) notice: proposed sale of 1,000 shares - Stock Titan
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $130 to $160 - Moomoo
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting - BioSpace
Stifel reiterates Guardant Health stock rating on screening outlook - Investing.com
Stifel reiterates Guardant Health stock rating on screening outlook By Investing.com - Investing.com Canada
Blood tests for cancer: 38 Guardant studies at 2026 ASCO meeting - Stock Titan
People who skip colorectal cancer screening because colonoscopy or stool testing seems too burdensome now have a blood test option from Guardant Health among recommendations by the American Cancer Society for detecting the disease, the medical gr - 97.5 Glory FM
Guardant Health Stock Rockets 34% With 7-Day Winning Streak - Trefis
Guardant Health Stock On Fire: Up 34% With 7-Day Winning Streak - Trefis
Finanzdaten der Guardant Health Inc-Aktie (GH)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
2.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):